Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
vCP1452 and IL-2 in HIV
NCT00013663Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ALVAC-HIV and aldesleukin in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Mean log10 viral load. Status: completed.
02
Drugs
ALVAC-HIValdesleukin
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00013663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00013663.